Clinical trial
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid…
NCT00103844 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00103844 |
|---|---|
| Title | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia |
| Official title | A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Dasatinib, Imatinib |
| Enrollment | 150 |
| Start date | Feb 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Feb 16, 2005 |
| Last update posted | Aug 10, 2010 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Estonia, Finland, France, Germany and 20 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: